THE EFFICACY OF SGLT2 (sodium–glucose cotransporter 2) INHIBITORS IN THE TREATMENT OF HEART FAILURE
Keywords:
SGLT2 inhibitors; heart failure; dapagliflozin; empagliflozin; HFrEF; HFmrEF (heart failure with mildly reduced ejection fraction); HFpEF (heart failure with preserved ejection fraction); cardiovascular outcomes; hospitalization.Abstract
Heart failure (HF (heart failure)) continues to be an important cause of hospitalization, disability, and cardiovascular mortality. Sodium–glucose cotransporter 2 (SGLT2) inhibitors, initially developed as glucose-lowering agents, are now regarded as disease-modifying treatment across the spectrum of left ventricular ejection fraction (LVEF (left ventricular ejection fraction)). Objective: To review the mechanisms of action, therapeutic efficacy, cardiovascular and kidney outcomes, safety profile, and contemporary clinical role of SGLT2 inhibitors in heart failure. Methods: A narrative, non-systematic synthesis of pivotal randomized trials including DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, DELIVER, and EMPULSE, together with contemporary ESC (European Society of Cardiology) guidance and recent scientific statements. Results: In HFrEF (heart failure with reduced ejection fraction), dapagliflozin and empagliflozin lowered the risk of worsening HF or cardiovascular death by approximately one quarter in pivotal trials. In HF with LVEF >40%, empagliflozin in EMPEROR-Preserved reduced cardiovascular death or HF hospitalization (HR (hazard ratio) 0.79), while dapagliflozin in DELIVER reduced cardiovascular death or worsening HF (HR 0.82). The observed benefits were largely unrelated to the presence or absence of diabetes and were also associated with fewer HF hospitalizations and favorable renal effects. Conclusions: Dapagliflozin and empagliflozin represent effective foundational treatments for HF across the LVEF spectrum. Their clearest and most reproducible benefit is prevention of worsening HF and hospitalization, with additional cardiorenal advantages and a generally favorable safety profile.
References
1.McMurray J. J. V., Solomon S. D., Inzucchi S. E. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction // New England Journal of Medicine. — 2019. — Vol. 381. — P. 1995–2008. — DOI: 10.1056/NEJMoa1911303.
2.Packer M., Anker S. D., Butler J. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure // New England Journal of Medicine. — 2020. — Vol. 383. — P. 1413–1424. — DOI: 10.1056/NEJMoa2022190.
3.Anker S. D., Butler J., Filippatos G. et al. Empagliflozin in heart failure with a preserved ejection fraction // New England Journal of Medicine. — 2021. — Vol. 385. — P. 1451–1461. — DOI: 10.1056/NEJMoa2107038.
4.Solomon S. D., McMurray J. J. V., Claggett B. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction // New England Journal of Medicine. — 2022. — Vol. 387. — P. 1089–1098. — DOI: 10.1056/NEJMoa2206286.
5.Voors A. A., Angermann C. E., Teerlink J. R. et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial // Nature Medicine. — 2022. — Vol. 28. — P. 568–574. — DOI: 10.1038/s41591-021-01659-1.
6.McDonagh T. A., Metra M., Adamo M. et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // European Heart Journal. — 2023. — Vol. 44. — P. 3627–3639. — DOI: 10.1093/eurheartj/ehad195.
7.Vaduganathan M., Docherty K. F., Claggett B. L. et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials // Lancet. — 2022. — Vol. 400. — P. 757–767. — DOI: 10.1016/S0140-6736(22)01429-5.
8.American Diabetes Association Professional Practice Committee. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 // Diabetes Care. — 2026. — Vol. 49, Suppl. 1.
9.European Society of Cardiology Heart Failure Association. SGLT2 inhibitors for the prevention and treatment of heart failure: scientific statement // ESC Heart Failure. — 2025.
